BCEIA 2023學術(shù)報告會大會報告嘉賓揭曉

時間：2023年9月6日
地點：學術(shù)會議區(qū)W201
邀請全球知名科學家介紹DNA存儲、納米毒理學等前沿科學技術(shù)，分享球差電鏡、微型化雙光子顯微鏡等高端儀器的研究進展，同時就質(zhì)譜法和核磁共振法等研究生物大分子結(jié)構(gòu)及功能、新型分離介質(zhì)制備及蛋白藥物、疫苗純化等最新應用進行探討和展望。
Paul Westerhoff
教授, 美國亞利桑那州立大學

 
報告題
目：Analytical Strategies to Assess PFAS Removal and Lifecycle Fate during Adsorption or Transformative Water Treatment Processes
報告摘要
Per- and polyfluoroalkyl substances (PFAS) occur in ground and surface water sources across the globe, and proposed drinking water regulations are driving PFAS treatment technology development and implementation. This presentation will first address current treatment technologies, which utilize adsorption (liquid to solid phase transformation), membranes (liquid to liquid separations) or transformative (oxidation or reduction) processes. Examples will be provided how treatment process efficiencies for “real waters” and how the processes challenge analytical methods. Second, the presentation addresses end-of-life for residuals (e.g., activated carbon) that contains PFAS, which will require incineration. Tracking PFAS during incineration requires unique analytical approaches to track fluorinated aqueous, gaseous and solid-phase species. Overall, the presentation will demonstrate how to match PFAS analytical strategies to PFAS drinking water treatment processes. 
個人簡介
Dr. Paul Westerhoff is a Regents Professor and Fulton Chair of Environmental Engineering in the School of Sustainable Engineering and the Built Environment at Arizona State University. Since joining ASU he has held various administrative positions. After serving as the Civil and Environmental Engineering Department Chair he was the Founding Director for the School of Sustainable Engineering and the Built Environment, and served later as Associate & Vice Dean of Research in Engineering and ASU Vice Provost for Academic Programming. Dr. Westerhoff is the Deputy Director of a NSF ERC for Nanotechnology Enabled Water Treatment and co-Deputy Director of the NSF STC Science and Technologies for Phosphorus Sustainability Center. His research group addresses questions related to What pollutants exist in the environment? If they occur, do they matter? If they occur and matter, what do we do to address them? with a focus on pollutants in natural and engineered water systems. He has over 400 journal publications (H-index>100) and multiple patents. He is the recipient of the 2020 A.P. Black award, 2019 NWRI Clarke Prize, 2015 ASU Outstanding Doctoral Mentor, 2013 ARCADIS/AEESP Frontier in Research Award, and 2006 Paul L. Busch Award. He was elected to the National Academy of Engineering in 2023.

Paul Breitenbecher
CEO, Breiten Associates LLC


報告題目：False positive, negative, and unexpected Drug Testing Results in the Urine Toxicology Laboratory |藥物測試：尿液毒理學實驗室使用篩選法（免疫測定法）和確認法（MS）
報告摘要
In 1995 I co-authored a  short article entitled “False-positive Immunoassay Results for Urine Benzodiazepine in Patients Receiving Oxaprozin (Daypro)”. This was published when rapid urine drug screening test methods were first becoming available. The laboratory community was starting to realize that not all assays can be tested for all of the thousands of drugs, substances or endogenous compounds that may potentially cause result errors. 
There are false positive, false negative and unexpected patient urine drug test results that occur in the Urine Toxicology laboratory. 
How does one research these results and assist the clinician in helping to assess these results to treat their patient?
Unexpected urine drug test results can occur during any phase of the testing process; however, the most common usual results occur  during the pre- analytical or patient collection phase. During this phase patients can provide “fake” urine, take substances that can affect the testing method, or they can adulterate/dilute their urine specimen.
Depending on the screening test method used, the test method can be impacted by a variety of substances that can produce either false negative, false positive or usual results. Screening results can also be different than the confirmation results making interpretation of patient results even more confusing.
During this presentation we will review a basic screening test method and confirmation method. And discuss some of these unexpected urine drug test results. 
個人簡介
Paul Breitenbecher在羅得島大學、康涅狄格大學、杜肯大學等高校進修了研究生課程，曾在哈佛先鋒醫(yī)學中心、諾華生物醫(yī)學研究院、病理實驗室公司（Inform Diagnostics，原名Miraca Life Sciences Inc.）等知名醫(yī)學機構(gòu)和企業(yè)的實驗室從事管理工作�，F(xiàn)任Breiten Associates LLC公司的首席執(zhí)行官，為臨床實驗室和CRO領(lǐng)域的科研人員提供采購、咨詢等方面的技術(shù)支持。

Robert Wielgosz
國際計量局（BIPM）化學部主任


報告題目：Certified Reference Materials for a Global Greenhouse Gas Monitoring Infrastructure 
報告摘要
Understanding sources and sinks of Greenhouse Gases (GHG) and the impact of policies to mitigate emissions provides a key tool for action against Climate Change. GHG emissions and uptake can be determined through measurement systems that include in situ measurement of GHG concentration at varying levels of spatial distribution. These measurements together with wind-speed measurements and numerical weather prediction and dispersion models can be used to determine spatially and time resolved GHG emissions and sinks. Maintaining a global system of such measurements, as envisaged, for example, by the WMO initiative on a coordinated global Greenhouse Gas Monitoring Infrastructure, requires close attention to quality assurance and equivalence of measurements from different sites.  Significant emissions may lead to small changes in GHG concentration, requiring highly consistent calibration standards at different measurement sites. The presentation will cover the establishment and characterization of CO2 in air standards for the measurements of concentration as well as isotope ratio, for source apportionment, that are required in GHG measurement networks. Generating the highest precision measurements of CO2 in air requires adopting metrological traceability to defined sets of primary standards, the so-called scale approach. The conversion of CO2 in air amount fraction values from one scale to another requires the scale relationships to be well known, noting that the requirement for internal consistency of standards within a scale, such as the WMO-CO2-X2019 scale, is at the 0.01 μmol/mol level, and consistency between different scales should not exceed the 0.02 μmol/mol level [1].  Certified reference materials that are needed to calibrate both in-situ based optical/laser based GHG amount faction and isotope ratio measurements as well as mass spectrometric laboratory-based measurements of isotope ratio will be described, as well as on-going comparisons to verify their equivalence. These comparisons are supporting National
個人簡介
Robert Wielgosz博士是位于法國的國際計量局（BIPM）化學部的主任，其氣體計量實驗室負責組織空氣質(zhì)量和溫室氣體標準國際比對。這些比對為由國家計量院（NMIs）和指定機構(gòu)（DIs）組成的世全球大氣監(jiān)測網(wǎng)絡(luò)提供標準支撐。他是國際計量委員會（CIPM）氣候變化和環(huán)境領(lǐng)域任務(wù)組成員，也是國際計量局-世界氣象組織（WMO）“氣候行動中的計量”研討會指導委員會主席。他發(fā)表測量科學相關(guān)論文60余篇，包括世界氣象組織大氣氣體成分測量指南。他擁有劍橋大學伊曼紐爾學院（英國）的自然科學碩士學位，巴斯大學（英國）的博士學位，并在烏爾姆大學（德國）完成了皇家學會歐洲交流研究。

Oliver J. Schmitz
教授德國杜伊斯堡-埃森大學

報告題目：Development of a New Ionization Source for Single Cell Metabolome Analysis
報告摘要
Although the unrevealing of cellular heterogeneity is limiting for the understanding of complex processes in cancer research as e.g. its influence on the process of metastasising, current research still depends on bulk analysis technologies as no reliable method could be established for real single cell metabolome analysis yet.
The necessary analytical requirements that such a method for single cell metabolome analysis needs in terms of detection limit, sample amount and specificity will be discussed in detail in this presentation. Also, still unsolved problems will be addressed and put up for discussion.
Subsequently, our current work on an ion source, which should be able to destroy the cell and thus release the analytes and ionize them by means of Dielectric Barrier Discharge, will be presented. The current status of developments from the literature and from us will be briefly presented in this talk.
個人簡介
In 2009 Oliver J. Schmitz got a full professor in Analytical Chemistry at the University of Wuppertal (BUW). Between 2010 and 2012 he was the chair of the Analytical Chemistry department at BUW. Since 2013, Schmitz has been a full professor at the University of Duisburg-Essen and heads the Institute for Applied Analytical Chemistry.
2009 he cofounded the company iGenTraX UG which develops new ion sources and units to couple separation techniques with mass spectrometers. In 2011 he was one of the founding directorsof the Interdisciplinary Centre for Pure and Applied Mass Spectrometry, University of Wuppertal. Since 2013, Schmitz is also one of the chairmen of the analytica conferences in China and Vietnam and in 2018, together with Agilent Technologies, he founded the Teaching and Research Center for Separation (TRC).
The research fields of Prof. Schmitz are the development of ion sources, use and optimization of multi-dimensional LC and GC, ion mobility-mass spectrometry and coupling analytical techniques with mass spectrometers. Furthermore, he is working about origin of life and metabolomics. Prof. Schmitz was awarded the scholar-in-training award of the American Association for Cancer Research in 2003, the Gerhard-Hesse Prize for chromatography in 2013 and in the same year the Fresenius Lecturer. 2018 he was awarded with the Waksmundzki Medal Award for Analytical Chemistry of the Polish Academy of Sciences. 
   
馬光輝
中國科學院院士
美國醫(yī)學與生物工程院（AIMBE）fellow
中國科學院過程工程研究所研究員
生化工程國家重點實驗室主任
中國顆粒學會副理事長
中國化學會會士
中國化工學會會士
中國微米納米技術(shù)學會會士
中國化工學會生物化工專業(yè)委員會副主任委員
中國生物工程學會生物基材料專業(yè)委員會主任委員


報告題目：新型分離介質(zhì)的制備和蛋白藥/疫苗純化應用Preparation of Novel Microspheres for Protein / Vaccine Separation Application
Polysaccharide particles such like agarose particles have been widely used in protein separation and purification as chromatographic packing materials by biological scientists and in industry. However, the limitation of conventional agarose particles is that the separation resolution is limited due to their broad size distribution. Furthermore, the particles with large size are usually used for industrial separation and purification to avoid the increase of back-pressure, which also limit the separation resolution. On the other hand, the particulate vaccine such like virus-like particle (VLP) has attracted more and more attention, conventional agarose particles with small pore size not only limited the adsorption of VLP, but also enhanced the disassociation of VLP, resulting very low activity recovery of VLP.We have developed a novel membrane process to prepare uniform agarose particle. By this technique we can control the CV (coefficient of variation) value which representing the size distribution around 15%, and we can prepare small uniform particles with high agarose concentration. Therefore, we can use small particles instead of large particles, and increase the separation resolution and flow rate of chromatography.  We have developed a new process to prepare giga-porous particle with pore size controllable between 100nm to 500 nm, and we found that it not only increased the loading amount of VLP, but also avoided the disassociation of VLP. This was because large pore size weakened the multi-site interaction between VLP and pore. This novel particle has been used for production of particulate vaccine instead of ultra-high speed centrifugation technique, much higher recovery was achieved.
個人簡介
馬光輝，中國科學院院士，美國醫(yī)學與生物工程院（AIMBE）fellow，生化工程國家重點實驗室主任。國家杰出青年獲得者，基金委創(chuàng)新群體首席，中國顆粒學會副理事長，中國化學會會士、中國化工學會會士、中國微米納米技術(shù)學會會士、中國化工學會生物化工專業(yè)委員會副主任委員、中國生物工程學會生物基材料專業(yè)委員會主任委員。研究方向為均一生物微球和微囊的制備及其在生化工程和醫(yī)學工程中的應用，研究和開發(fā)用于生化分離、藥物載體、免疫佐劑（疫苗遞送系統(tǒng)）、細胞培養(yǎng)微載體、酶固定化載體等創(chuàng)新產(chǎn)品。在Nat. Mater., Sci. Transl. Med., Nat. Nanotechnol., Nat. Biomed. Eng., Sci. Adv., Nat. Commun., JACS, Adv. Mater.等國際著名學術(shù)期刊上發(fā)表SCI論文500余篇。出版中英文專著12部，撰寫學術(shù)書章節(jié)22篇。中國發(fā)明專利授權(quán)81項，國際專利授權(quán)12項，專利技術(shù)和產(chǎn)品在國內(nèi)外500多家單位得到應用。獲國家技術(shù)發(fā)明二等獎、北京市科學技術(shù)一等獎、中國化工學會科學技術(shù)獎基礎(chǔ)研究成果獎一等獎、中國顆粒學會自然科學獎一等獎、中國石油和化學工業(yè)聯(lián)合會技術(shù)發(fā)明一等獎、侯德榜化工科技創(chuàng)新獎、“中國科協(xié)全國優(yōu)秀科技工作者”稱號。

程和平
中國科學院 院士
北京大學未來技術(shù)學院 教授
北京大學分子醫(yī)學南京轉(zhuǎn)化研究院 院長
北京大學國家生物醫(yī)學成像科學中心 主任
國家十三五重大科技設(shè)施“多模態(tài)跨尺度生物醫(yī)學成像設(shè)施” 首席科學家


報告題目：科技鑄器，開啟腦科學研究新范式
腦科學研究包括“讀、釋、寫、仿”四個方面，是一門高度交叉的新興前沿學科。為開發(fā)“讀、釋、寫、仿”工具，團隊于2017年成功研發(fā)了2.2克微型化雙光子顯微鏡，實現(xiàn)了在自由行為小鼠觀察大腦神經(jīng)元活動，開啟腦科學研究的新范式。2021年，第二代微型化雙光子顯微鏡問世，實現(xiàn)了三維空間中近千個神經(jīng)元的功能成像，開啟了在自由行為動物研究大腦神經(jīng)元結(jié)構(gòu)和功能的新范式。2023年成功研發(fā)了2.17克的微型化三光子顯微鏡，首次實現(xiàn)對自由行為中小鼠的大腦全皮層和海馬神經(jīng)元功能成像，為揭示大腦深部神經(jīng)機制提供了又一利器。為支撐中國的“腦計劃”，我們建設(shè)了“南京腦觀象臺”，由相關(guān)領(lǐng)域?qū)＜翌I(lǐng)銜，正在開展腦科學“探索計劃”項目，主題涉及皮質(zhì)工作記憶、睡眠、自閉癥、抑郁癥、神經(jīng)藥理學和神經(jīng)元再生等。作為國之重器，“多模態(tài)跨尺度生物醫(yī)學成像設(shè)施”（國家十三五重大科技基礎(chǔ)設(shè)施）的建設(shè)正在如火如荼地展開，預期于今年底投入試運行，2024年完成國家驗收。依托此成像大設(shè)施，已啟動“早鳥項目”，面向全國科技界滾動征集合作立項建議，計劃在未來3-5年內(nèi)發(fā)起生命科學包括腦科學領(lǐng)域的大科學計劃，充分發(fā)揮“科技航母”的戰(zhàn)略價值。大科學時代的生命科學特別需要新的工具，需要新型的研究平臺。未來，更多新工具的開發(fā)以及新范式的探索，特別是大科學時代有組織科研的新范式，將為提升我國生物醫(yī)學研究的整體水平，尤其是原始創(chuàng)新能力，實現(xiàn)高端生物醫(yī)學儀器裝備的“中國創(chuàng)造”提供強有力的戰(zhàn)略支撐和保障。
個人簡介
程和平院士長期致力于鈣信號、線粒體生物醫(yī)學領(lǐng)域的研究，以及高端生物醫(yī)學儀器的自主創(chuàng)制。主要學術(shù)貢獻為 ① 發(fā)現(xiàn)細胞鈣信號基本單位—“鈣火花”（Calcium Spark），原始論文曾被譽為100多年來十篇最杰出的心肌研究論文之一； ② 發(fā)現(xiàn)線粒體 “超氧炫”又稱“線粒體炫”（Mitoflash），揭示其在能量代謝、學習記憶及衰老生物學中的信號功能；③率團隊研發(fā)2.2克微型雙光子顯微鏡，實現(xiàn)了在自由活動小鼠觀察大腦神經(jīng)元活動，開啟腦科學研究的新范式。該項成果獲“2017年中國科學十大進展”，并入選Nature Methods“2018年度方法”。此外，獲國際心臟學會“Research Achievement Award”(2016），國家自然科學獎二等獎 （2017），何梁何利基金科學與技術(shù)進步獎（2020），北京大學2021年度國華杰出學者獎（2021），中國專利優(yōu)秀獎（2022）等。